Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
Launched by ASTRAZENECA ·
Trial Information
Current as of September 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how men with a specific type of prostate cancer, called de novo metastatic hormone-sensitive prostate cancer, are being treated in Russia. It also looks at certain biological markers (called biomarkers) that can help doctors understand the disease better. The study is observational, which means it will watch and collect information about patients’ treatments and health without changing what doctors decide to do.
Men between the ages of 65 and 74 who have just been diagnosed with this type of prostate cancer may be eligible to join. Participants can expect to share information about their treatment and health during their regular doctor visits. This study does not involve new treatments or medications but helps researchers learn more about current care practices and disease characteristics to improve future prostate cancer care.
Gender
MALE
Eligibility criteria
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported